Synthesis and biological evaluation of some novel cyclic-imides as hypoglycaemic, anti-hyperlipidemic agents

Certain new halogenated cyclic-imides related to N-substituted phthalimide moiety were synthesized. Spacers of one or two carbon atom distances were inserted to connect the N-terminus of the cyclic-imide nuclei to the used heteroaryl groups to evaluate the effect of such alteration on biological activity. The synthesized compounds were subjected to hypoglycaemic and anti-hyperlipidemic evaluation. Some of the tested compounds proved to be more potent than the reference drugs glibenclamide and clofibrate. Compound 5e remarkably reduced serum glucose level by 55%; while 5c, 5e, 7d and 8e reduced total serum cholesterol by 58, 56, 54 and 53%, respectively. Those new cyclic-imides could be considered as useful template for future development to obtain more potent hypoglycaemic and anti-hyperlipidemic agents.

Compound 5e remarkably reduced serum glucose level by 55%; while 5c reduced total serum cholesterol by 58%, using glibenclamide and clofibrate as positive controls.Figure optionsDownload as PowerPoint slideHighlights
► Halogenated cyclic-imides related to N-phthalimide moiety were synthesized.
► Hypoglycaemic and anti-hyperlipidemic activities of the new compounds were evaluated.
► Compound 5e reduced serum glucose level by 55%.
► Compounds 5c, 5e, 7d and 8e reduced total serum cholesterol by 58, 56, 54 and 53%, respectively.